Spirogen's strategy is to develop a portfolio of products for the global market in the areas of oncology and anti-infectives both in-house and in collaboration with partners. The products utilize our proprietary, patented small molecule DNA base pair recognition technology. Spirogen partners products at the IND stage or Phase 2. The technology may be applied in oncology and other therapeutic areas in field specific discovery research collaborations.
